Adage Capital Partners Portfolio holdings
AUM
$59.3B
1-Year Return
26.26%
This Quarter Return
+5.25%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$57.2B
AUM Growth
+$551M
(+0.97%)
Cap. Flow
-$296M
Cap. Flow
% of AUM
-0.52%
Top 10 Holdings %
Top 10 Hldgs %
31.76%
Holding
1,007
New
143
Increased
295
Reduced
385
Closed
137
Top Buys
| 1 |
ConocoPhillips
COP
|
+$230M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$185M |
| 3 |
WESCO International
WCC
|
+$171M |
| 4 |
Gilead Sciences
GILD
|
+$158M |
| 5 |
Delta Air Lines
DAL
|
+$148M |
Top Sells
| 1 |
MRO
Marathon Oil Corporation
MRO
|
+$221M |
| 2 |
3M
MMM
|
+$154M |
| 3 |
Marsh & McLennan
MMC
|
+$115M |
| 4 |
Johnson & Johnson
JNJ
|
+$99M |
| 5 |
Novo Nordisk
NVO
|
+$94.6M |
Sector Composition
| 1 | Technology | 29.09% |
| 2 | Healthcare | 13.87% |
| 3 | Financials | 11.48% |
| 4 | Consumer Discretionary | 10.65% |
| 5 | Industrials | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
501
Baker Hughes
BKR
$45.9B
| $15.4M | 0.03% |
374,502
-96,900
| -21% | -$3.97M |
|
502
TE Connectivity
TEL
$62.5B
| $15.2M | 0.03% |
106,073
-97,871
| -48% | -$14M |
|
|
NARI
503
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $15.1M | 0.03% |
+296,543
| New | +$15.1M |
|
504
Eastman Chemical
EMN
$7.7B
| $15.1M | 0.03% |
165,343
+25,200
| +18% | +$2.3M |
|
505
Tradeweb Markets
TW
$25.4B
| $15.1M | 0.03% |
+115,000
| New | +$15.1M |
|
506
Factset
FDS
$13.9B
| $15M | 0.03% |
31,300
+17,900
| +134% | +$8.6M |
|
507
LXP Industrial Trust
LXP
$2.68B
| $15M | 0.03% |
1,850,000
+700,000
| +61% | +$5.68M |
|
508
Oneok
OKE
$45.7B
| $14.9M | 0.03% |
148,300
-167,300
| -53% | -$16.8M |
|
509
SiriusXM
SIRI
$8.08B
| $14.8M | 0.03% |
650,722
-600,000
| -48% | -$13.7M |
|
510
Viavi Solutions
VIAV
$2.64B
| $14.7M | 0.03% |
1,455,590
-780,612
| -35% | -$7.88M |
|
|
BBOT
511
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$805M
| $14.7M | 0.03% |
1,400,000
| – | – |
|
512
Enliven Therapeutics
ELVN
$1.19B
| $14.6M | 0.03% |
650,000
-150,000
| -19% | -$3.38M |
|
513
Kenvue
KVUE
$35.6B
| $14.6M | 0.03% |
683,258
-2,012,173
| -75% | -$43M |
|
514
Lexeo Therapeutics
LXEO
$287M
| $14.5M | 0.03% |
2,209,615
-388,121
| -15% | -$2.55M |
|
515
Advanced Drainage Systems
WMS
$11B
| $14.5M | 0.03% |
125,000
+92,000
| +279% | +$10.6M |
|
516
BorgWarner
BWA
$9.34B
| $14.4M | 0.03% |
454,306
+239,600
| +112% | +$7.62M |
|
|
AEVA
517
Aeva Technologies
AEVA
$840M
| $14.4M | 0.03% |
3,035,162
-781,590
| -20% | -$3.71M |
|
518
Antero Resources
AR
$10.2B
| $14.4M | 0.03% |
410,696
| – | – |
|
519
Loews
L
$19.9B
| $14.3M | 0.03% |
168,900
-2,800
| -2% | -$237K |
|
|
INZY
520
DELISTED
Inozyme Pharma
INZY
| $14.3M | 0.03% |
5,160,000
-513,629
| -9% | -$1.42M |
|
521
Humana
HUM
$31.9B
| $14.2M | 0.02% |
55,962
-35,486
| -39% | -$9M |
|
522
PTC
PTC
$24.6B
| $14.2M | 0.02% |
77,200
+7,500
| +11% | +$1.38M |
|
523
Alliant Energy
LNT
$16.5B
| $14.2M | 0.02% |
+239,708
| New | +$14.2M |
|
524
Dollar Tree
DLTR
$20.2B
| $14.2M | 0.02% |
188,838
-1,600
| -0.8% | -$120K |
|
525
Fulcrum Therapeutics
FULC
$380M
| $14.1M | 0.02% |
3,000,000
+1,000,000
| +50% | +$4.7M |
|